ETNB实时信号 | 通过Getagraph.com最大化利润

购买 107594 min ago

@ $9.72

发出时间: 15 Feb 2024 @ 03:51

回报率: -15.02%

上一信号: Feb 14 - 23:22

上一信号: 出售

回报率: 7.40 %

Live Chart Being Loaded With Signals

Commentary (27 Apr 2024 @ 04:00):

89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases...

Stats
今日成交量	653 066
平均成交量	1.27M
市值	772.32M
EPS	$0 ( 2024-03-08 )
下一个收益日期	( $-0.480 ) 2024-05-02
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-4.13
ATR14	$0.0110 (0.13%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-13	Babler Martin	Buy	0
2024-04-11	Ra Capital Management, L.p.	Buy	1 408 450	Common Stock
2024-02-01	Ra Capital Management, L.p.	Buy	45 150	Stock Option (Right to Buy)
2023-02-09	Ra Capital Management, L.p.	Buy	27 400	Stock Option (Right to Buy)
2024-04-11	Ra Capital Management, L.p.	Sell	2 816 900	Warrants (Right to Buy)

INSIDER POWER
35.41
Last 99 transactions
Buy: 8 649 796 \| Sell: 3 351 793

音量相关性

長: -0.15 (neutral)

短: -0.73 (moderate negative)

Signal:(49.338) Neutral

89Bio Inc 相关性

10 最正相关
IVAC	0.891
LRFC	0.891
KRMD	0.889
EDTK	0.883
OCAX	0.881
ASO	0.877
GEEX	0.876
LYTS	0.875
HOFT	0.875
ALOR	0.873

10 最负相关
IMGN	-0.891
NKTX	-0.886
HOL	-0.88
INPX	-0.877
IMPP	-0.876
CLFD	-0.875
GRNA	-0.873
BIOL	-0.873
PMVP	-0.873
SNCE	-0.871

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

89Bio Inc 相关性 - 货币/商品

0.69
( moderate )

0.71
( moderate )

0.00
( neutral )

0.17
( neutral )

0.73
( moderate )

-0.80
( moderate negative )

89Bio Inc 财务报表

Annual	2023
营收:	$0
毛利润:	$-273 000 (0.00 %)
EPS:	$-2.00

FY	2023
营收:	$0
毛利润:	$-273 000 (0.00 %)
EPS:	$-2.00

FY	2022
营收:	$0
毛利润:	$-240 000 (0.00 %)
EPS:	$-2.93

FY	2021
营收:	$0.00
毛利润:	$0.00 (0.00 %)
EPS:	$-4.48

Financial Reports:

No articles found.

89Bio Inc

89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also intends to develop pegozafermin for the treatment of severe hypertriglyceridemia. 89bio, Inc. was incorporated in 2018 and is headquartered in San Francisco, California.

实时更新： 89Bio Inc [ETNB]

Upcoming Earnings Alert